FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
Global Silicone Elastomers Market Analysis 2016 - Forecast to 2022 - Research and Markets
Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy
This iShares’ ETF has appeal, but investors don't have to go much further afield to find more-compelling options.
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
Large drugmakers are out of favor, but some good funds are banking on a rebound.